Tensions rise in Korea's pharma sector as Trump plans drug tariffs. Companies like Samsung Biologics monitor the situation ...

Samsung Biologics announced on April 28 that it had signed a 737.3 billion won ($5.4 billion) contract to manufacture pharmaceutical products for a U.S.-based company. This marks its second major ...

Samsung Biologics, which has enjoyed a booming contract drug manufacturing streak over the past year, has inked another ...

Samsung Biologics Logo (PRNewsfoto/Samsung Biologics) "We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our ...